# AIM — AIM ImmunoTech Inc · catalysts, narrative & risks

**Deep-research report — K3vl4r**  
**Symbols:** AIM  
**Sources:** 15  
**Published:** 2026-10-03  
**Canonical:** https://app.k3vl4r.com/research/deep-research-aim-aim-immunotech-inc-catalysts-narrative-risks-5931

---

# AIM ImmunoTech Inc. (NYSE American: AIM)

## Recent Catalysts (roughly July–October 2026)

The most significant recent activity centers on the company's lead candidate **Ampligen® (rintatolimod)** and its pancreatic cancer program:

---

_Preview only. The complete multi-source deep-research report — full thesis, evidence, and citations — is available at https://app.k3vl4r.com/research/deep-research-aim-aim-immunotech-inc-catalysts-narrative-risks-5931 (free to sign up)._
